Baxter International (Baxter International) Cash And Cash Equivalents

: $3,194 Mil (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

Baxter International's quarterly cash and cash equivalents increased from Jun. 2023 ($1,722.00 Mil) to Sep. 2023 ($5,788.00 Mil) but then stayed the same from Sep. 2023 ($5,788.00 Mil) to Dec. 2023 ($3,194.00 Mil).

Baxter International's annual cash and cash equivalents declined from Dec. 2021 ($2,951.00 Mil) to Dec. 2022 ($1,718.00 Mil) but then increased from Dec. 2022 ($1,718.00 Mil) to Dec. 2023 ($3,194.00 Mil).

Baxter International Cash And Cash Equivalents Historical Data

The historical data trend for Baxter International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

3,335.00

3,730.00

2,951.00

1,718.00

3,194.00

Baxter International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																1,718.00	1,673.00	1,722.00	5,788.00	3,194.00

Baxter International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Baxter International (NYSE:BAX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Baxter International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Baxter International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxter International (Baxter International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

1BAX:Italy BTL:Germany BTL:Germany BTL:Germany BAX:Austria

Address

One Baxter Parkway, Deerfield, IL, USA, 60015

Website

https://www.baxter.com

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

Executives

Joel T. Grade	officer: EVP, Chief Financial Officer	SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth	officer: EVP, Group Pres, Kidney Care	1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul	officer: EVP, Group Pres, Healthcare	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig	officer: EVP, Group President, Pharm	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight	officer: EVP, Group Pres, Medical	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler	officer: SVP, Chief Quality Officer	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason	officer: CVP, Human Resources	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn	officer: SVP, President, APAC	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver	director
David Brent Shafer	director	2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith	director	TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403